Clinical Trial Update: Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating lapatinib ditosylate in men with rising PSA indicating recurrent prostate cancer, with results posted after completio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Prostate Cancer, Stage I Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-04-13